CA2461631A1 - Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules - Google Patents

Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules Download PDF

Info

Publication number
CA2461631A1
CA2461631A1 CA002461631A CA2461631A CA2461631A1 CA 2461631 A1 CA2461631 A1 CA 2461631A1 CA 002461631 A CA002461631 A CA 002461631A CA 2461631 A CA2461631 A CA 2461631A CA 2461631 A1 CA2461631 A1 CA 2461631A1
Authority
CA
Canada
Prior art keywords
antigen
tumor
binds
mammal
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002461631A
Other languages
English (en)
French (fr)
Inventor
David Jackson
Linda Nardone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elusys Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2461631A1 publication Critical patent/CA2461631A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002461631A 2001-09-28 2002-09-27 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules Abandoned CA2461631A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32573201P 2001-09-28 2001-09-28
US60/325,732 2001-09-28
PCT/US2002/031020 WO2003026490A2 (en) 2001-09-28 2002-09-27 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules

Publications (1)

Publication Number Publication Date
CA2461631A1 true CA2461631A1 (en) 2003-04-03

Family

ID=23269190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002461631A Abandoned CA2461631A1 (en) 2001-09-28 2002-09-27 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules

Country Status (4)

Country Link
EP (1) EP1487487A2 (de)
JP (1) JP2005510470A (de)
CA (1) CA2461631A1 (de)
WO (1) WO2003026490A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003095626A2 (en) * 2002-05-13 2003-11-20 Elusys Therapeutics, Inc. Purified composition of bispecific molecules and methods of production
WO2005045058A2 (en) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
EP1814918A1 (de) * 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Verwendung von cr1-bindenden molekülen bei der clearance und der induktion von immunreaktionen
JP2008530123A (ja) * 2005-02-09 2008-08-07 ジェネンテック・インコーポレーテッド マトリックスメタロプロテアーゼアンタゴニストを用いたｈｅｒ２のシェディングの阻害
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PL3221359T3 (pl) 2014-11-17 2020-11-16 Regeneron Pharmaceuticals, Inc. Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
AU2016242866B2 (en) 2015-03-30 2021-06-03 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to FC gamma receptors
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
CN108290951B (zh) * 2015-09-23 2022-04-01 瑞泽恩制药公司 优化抗cd3双特异性抗体和其用途
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies

Also Published As

Publication number Publication date
JP2005510470A (ja) 2005-04-21
WO2003026490A2 (en) 2003-04-03
WO2003026490A3 (en) 2004-10-21
EP1487487A2 (de) 2004-12-22

Similar Documents

Publication Publication Date Title
JP5185815B2 (ja) 抗ｃｄ７１モノクローナル抗体および悪性腫瘍細胞を治療するためのその使用
JP6389166B2 (ja) 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
ES2534288T3 (es) Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
CN109071642B (zh) 连接蛋白(Cx)43半通道结合抗体及其用途
US20230190796A1 (en) Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US20030026803A1 (en) Compositions for inhibiting macrophage activity
US20220064324A1 (en) Cross species single domain antibodies targeting mesothelin for treating solid tumors
US10246516B2 (en) Anti-La antibodies and their use for immunotargeting
CA2461631A1 (en) Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
US20120027763A1 (en) Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1
US20090053136A1 (en) Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells
AU2012277784B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
JP2022519377A (ja) がんのバイオマーカーとしてのｉｌ－４ｒ
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
US20240084011A1 (en) Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
EP4261225A1 (de) Anti-pd-1-antikörper und verwendungen davon
AU2002340069A1 (en) Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
CN116535509B (zh) 抗CD79b抗体、其制备方法及其应用
JP2016013104A (ja) 抗イヌｃｄ２０モノクローナル抗体又は抗体フラグメント、キット、診断方法、治療用組成物、治療方法、核酸、ベクター、キメラ抗原受容体及びｔ細胞
CN116444672B (zh) 人表皮生长因子3的抗体、其制备方法及其应用
AU2002306728A1 (en) Polyclonal populations of bispecific molecules and methods of production and uses thereof
WO2002075275A2 (en) Polyclonal populations of bispecific molecules and methods of production and uses thereof
US20040109863A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9
EP4346887A1 (de) C-x-c motiv chemokine rezeptor 6 (cxcr6) bindende moleküle und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060927